Clinical TrialOct 23, 2026, 06:46 AM
Tango Therapeutics: Vopimetostat Trial Shows 82% ORR in PDAC Patients
AI Summary
Tango Therapeutics announced promising updated results from its Phase 1/2 clinical trial evaluating vopimetostat in combination with RAS(ON) inhibitors. The combination of vopimetostat and daraxonrasib demonstrated an 82% objective response rate (ORR) and an 88% 9-month progression-free survival (PFS) rate in patients with second- or third-line MTAP-deleted/RAS-mutant pancreatic ductal adenocarcinoma (PDAC). The combination was generally well-tolerated at dose level 1. Based on these results and discussions with the FDA, Tango plans to initiate a registrational Phase 3 trial in front-line MTAP-deleted PDAC in the first half of 2027.
Key Highlights
- Tango Therapeutics announced updated Phase 1/2 trial results for vopimetostat in combination with RAS(ON) inhibitors.
- In 22 efficacy-evaluable patients with 2L/3L MTAP-deleted/RAS-mutant PDAC, vopimetostat + daraxonrasib showed an 82% ORR.
- Median PFS was not reached, and the 9-month PFS rate was 88% in the PDAC patient group.
- The combination was generally well-tolerated at dose level 1, with no DLTs or withdrawals due to TRAEs.
- A registrational Phase 3 study of vopimetostat + daraxonrasib in front-line MTAP-deleted PDAC is planned for 1H 2027.
- In NSCLC patients (n=5), vopimetostat + daraxonrasib showed an 80% ORR and 100% DCR at dose level 1.
- Vopimetostat + zoldonrasib showed a 54% ORR and 61% 9-month PFS rate in PDAC patients (n=35).
Price Impact
More from TNGX